sécurité sociale – Prise imposée de générique pour les femmes atteintes du cancer du sein

This written question concerns the social security system and the mandatory use of generic drugs for women diagnosed with breast cancer. It seeks clarification on the current policies and potential impacts on patient access to treatment. The question addresses the implications for patients, healthcare providers, and the pharmaceutical industry. It aims to understand how this policy change might affect treatment costs and the availability of specific medications.